The effect of atorvastatin on cognition and mood in bipolar disorder and unipolar depression patients: A secondary analysis of a randomized controlled trial

Jocelyn Fotso Soh, Ahmad Almadani, Serge Beaulieu, Tarek Rajji, Benoit H. Mulsant, Chien Lin Su, Suzane Renaud, Istvan Mucsi, S. Gabriela Torres-Platas, Andrea Levinson, Ayal Schaffer, Annemiek Dols, Pablo Cervantes, Nancy Low, Nathan Herrmann, Outi Mantere, Soham Rej

Research output: Contribution to journalArticle

Abstract

Objectives: Statins have recently been linked to having effects on cognition and mood in mood disorders, though results are mixed. In this paper, we use data from a recent randomized controlled trial (RCT) to examine the effect of statins on cognition and mood in patients with Bipolar Disorder (BD) and Major Depressive Disorder (MDD). Methods: This is a secondary analysis of a randomized, double-blind, placebo-controlled clinical trial (n = 60) originally designed to examine the effect of atorvastatin (n = 27) versus placebo (n = 33) for lithium-induced diabetes insipidus in BD and MDD patients who were using lithium. For this analysis, the primary outcome was global cognition Z-score at 12-weeks adjusted for baseline. The secondary cognition outcomes were (1) Screen for Cognitive Impairment in Psychiatry (SCIP), and (2) executive function Z-score. The primary mood outcome (secondary outcome of this analysis) was depression relapse during 12-week follow-up (Mongomery Asberg Depression Rating Scale (MADRS) ≥10). The secondary mood outcomes were (1) relapse rate into a manic episode, and (2) relapse rate into any mood episode. Results: After 12 weeks follow-up, atorvastatin and placebo groups did not differ in terms of global cognition Z-score (β = −0.009287 (−0.1698,0.1512), p-value = 0.91). Similarly, composite Z-scores for SCIP and executive functions did not differ significantly. Depression relapse during 12-week follow-up was not significantly different between the groups (χ2 (1) = 0.148, p-value = 0.70). Similarly, there was no difference between groups regarding relapse into mania. Conclusion: In BD and MDD patients with lithium-induced nephrogenic diabetes insipidus randomized to atorvastatin or placebo, we found no significant differences in cognition and mood outcomes at 12-week follow-up.

Original languageEnglish
Pages (from-to)149-154
Number of pages6
JournalJournal of affective disorders
Volume262
DOIs
Publication statusPublished - Feb 1 2020

    Fingerprint

Keywords

  • Bipolar disorder
  • Cognition
  • Major depressive disorder
  • Placebo
  • Randomized clinical trial
  • Statins

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Fotso Soh, J., Almadani, A., Beaulieu, S., Rajji, T., Mulsant, B. H., Su, C. L., Renaud, S., Mucsi, I., Torres-Platas, S. G., Levinson, A., Schaffer, A., Dols, A., Cervantes, P., Low, N., Herrmann, N., Mantere, O., & Rej, S. (2020). The effect of atorvastatin on cognition and mood in bipolar disorder and unipolar depression patients: A secondary analysis of a randomized controlled trial. Journal of affective disorders, 262, 149-154. https://doi.org/10.1016/j.jad.2019.11.013